Dutch gene therapy firm UniQure threw its hat into the RNAi ring this week, announcing that it has picked up non-exclusive access to Benitec Biopharma's proprietary expressed RNAi technology for use with its nascent Huntington's disease program.

In doing so, the company hopes to apply its core adeno-associated virus technology with the gene-silencing technology, potentially opening the door to other RNAi programs, Hans Preusting, UniQure senior vice president of business development, told Gene Silencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.